Jeffrey Salazar
Qsymia and Belviq are two prescription weight loss drugs that have been approved by the FDA. Both drugs are designed to suppress appetite and help people lose weight, but they work in different ways and have different side effects. While Qsymia combines two previously approved drugs, Belviq works by increasing levels of serotonin in the brain. This paragraph will explore the key differences between the two drugs and discuss which may be the better option for weight loss.
Explore related products
What You'll Learn
- Qsymia and Belviq are approved for similar problems: obesity and being overweight
- Qsymia is considered to have the biggest weight-loss advantage
- Belviq is considered less risky based on side-effect profiles
- Qsymia combines two currently approved drugs: phentermine and topiramate
- Belviq causes weight loss by increasing serotonin levels in the brain
Qsymia and Belviq are approved for similar problems: obesity and being overweight
Belviq (lorcaserin hydrochloride) decreases cravings for carbohydrate-rich foods by stimulating the release of serotonin, which is usually triggered by carbohydrate intake. On the other hand, Qsymia is a combination of phentermine and topiramate. Phentermine is a sympathomimetic amine with pharmacologic activity similar to amphetamine, which is used in obesity treatment. Topiramate is a seizure/migraine drug that causes weight loss in several ways, including increasing feelings of fullness, making foods taste less appealing, and increasing calorie burning.
The FDA notes that people who don't lose at least 3% of their body weight by three months are unlikely to go on to lose any significant weight, so they should either be counselled to discontinue the drug or to try a higher dose. If patients still don't lose at least 5% of their weight after three additional months on the higher dose, they should quit taking Qsymia.
Celiac Diet: What You Can and Can't Eat
You may want to see also
Explore related products
Qsymia is considered to have the biggest weight-loss advantage
Qsymia and Belviq are two prescription weight loss drugs that have been approved by the Food and Drug Administration (FDA). Both drugs are designed to treat obesity, defined as a body mass index (BMI) of 30 or greater, or being overweight with a BMI of 27 or more and at least one weight-related condition such as type 2 diabetes, high blood pressure, or high cholesterol. While both drugs are effective in helping people lose weight, Qsymia is considered to have the biggest weight-loss advantage.
In clinical trials, people taking Qsymia lost more weight compared to those taking Belviq. On average, patients taking Belviq lost about 5% to 5.8% of their total weight after a year, while Qsymia users lost about 10% of their body weight over two years. This significant difference in weight loss percentages is one of the key reasons why Qsymia is considered superior to Belviq in terms of weight-loss advantages.
The difference in weight loss results between the two drugs can be attributed to their distinct mechanisms of action. Qsymia combines two approved drugs: phentermine, an appetite suppressant, and topiramate, a seizure/migraine drug. Phentermine suppresses appetite by increasing blood concentrations of leptin, a hormone that regulates appetite. Topiramate, on the other hand, causes weight loss by increasing feelings of fullness, making foods less appealing, and increasing calorie burning. This combination of appetite suppression and increased calorie burning contributes to the higher weight loss percentage observed in Qsymia users.
It is important to note that Qsymia is not a "magic pill" and should not be relied upon as the sole solution for weight loss. The FDA recommends that Qsymia be used in conjunction with traditional weight-management strategies such as diet and exercise. Additionally, Qsymia may not be suitable for everyone, particularly pregnant women or those with cardiovascular issues, due to potential risks and side effects. However, for individuals seeking significant weight loss results, Qsymia has proven to offer a greater advantage when compared to Belviq.
In conclusion, while both Qsymia and Belviq are effective weight loss drugs, Qsymia surpasses Belviq in terms of weight-loss advantages. The higher percentage of weight loss achieved by Qsymia users, along with its unique combination of appetite suppression and increased calorie burning, solidifies its position as the preferred choice for individuals seeking substantial weight loss. However, it is essential to consult with a healthcare professional before starting any weight loss medication to ensure a safe and effective treatment plan.
SCD Diet: When to Introduce Cheese
You may want to see also
Explore related products
Belviq is considered less risky based on side-effect profiles
Diet pills have had a controversial history with the FDA, largely due to safety concerns, particularly involving the heart. Fenfluramine, for example, was withdrawn from the market due to safety hazards. Belviq and Qsymia are two new prescription weight loss drugs that have recently been approved by the FDA. Both medications are approved for similar problems, including obesity and being overweight with a BMI of 27 or more and at least one weight-related condition.
Belviq causes weight loss by turning on a specific switch that increases levels of the brain messenger serotonin. At dosages intended for weight loss, it does not significantly turn on slightly different serotonin switches responsible for the effects of hallucinogens or addictive drugs of abuse. On the other hand, Qsymia combines two currently approved drugs: phentermine, an appetite suppressant, and topiramate, a seizure/migraine drug. While Qsymia has shown greater weight loss results, Belviq is considered less risky due to the potential side effects of Qsymia's constituent drugs.
Phentermine is thought to suppress appetite by triggering the release of the brain chemical norepinephrine, which increases blood concentrations of the appetite-regulating hormone leptin. Topiramate, the other half of Qsymia, causes weight loss by increasing feelings of fullness, making foods taste less appealing, and increasing calorie burning. Obesity specialists consider Qsymia's 7.5-milligram dose of phentermine a reasonable risk unless the patient has cardiovascular issues—in which case any central nervous system stimulant is dangerous.
In conclusion, while Qsymia has shown greater weight loss results in clinical trials, Belviq is considered less risky based on side-effect profiles. Belviq's mechanism of action targets serotonin levels without significantly activating the pathways responsible for the effects of hallucinogens or addictive drugs. Qsymia, on the other hand, combines phentermine and topiramate, which may pose greater risks, especially for individuals with cardiovascular issues. As always, it is important to consult with a healthcare professional before taking any medication, including weight loss drugs.
Custom Dieting: Mastering Your Macros
You may want to see also
Explore related products
Qsymia combines two currently approved drugs: phentermine and topiramate
Qsymia is a prescription medicine that combines two currently approved drugs: phentermine and topiramate extended-release. Phentermine is a sympathomimetic that works in the brain to lower your appetite. It is a previously FDA-approved weight-loss medication. Topiramate is an antiepileptic (anti-seizure medication) that is also associated with weight loss as a side effect. Scientists are unsure of the exact mechanism by which topiramate helps people lose weight, but it is thought to lower appetite and increase the feeling of fullness.
Qsymia is the first weight-loss drug to be launched in the U.S. in 13 years. It is intended to be used as an adjunct to a reduced-calorie diet and increased physical activity in patients with a body mass index (BMI) greater than 30 kg/m2 or a BMI of 27 kg/m2 or greater, who also have at least one weight-related comorbidity. It is approved for people over 12 who are considered obese and for some adults who are considered overweight.
Qsymia has been proven to help with weight management in adults and children ages 12-17 when combined with a healthy diet and regular exercise. It is the #1 prescribed branded oral weight-management medication in adults and is FDA-approved for weight management in children ages 12-17.
Qsymia is available in two doses. The FDA notes that people who don’t lose at least 3% of their body weight by three months are unlikely to go on to lose any significant weight, so they should either be counselled to discontinue the drug or to try a higher dose. If patients still don’t lose at least 5% of their weight after three additional months on the higher dose, they should quit taking Qsymia.
Calorie Counting: 1200-Calorie Diet Meal Plan Explained
You may want to see also
Explore related products
Belviq causes weight loss by increasing serotonin levels in the brain
Qsymia and Belviq are two weight-loss drugs that have been approved by the Food and Drug Administration (FDA). Qsymia, made by Vivus Inc., was approved in July 2012, and Belviq (lorcaserin), made by Arena Pharmaceuticals, was approved in June 2012.
The exact mechanism of action of lorcaserin is not fully understood, but it is believed to selectively target 5-HT2C receptors. When the maximum dose of 20 mg/day is exceeded, lorcaserin binds more to other serotonin receptors such as 5-HT2A, which can lead to hallucinations, euphoria, and altered mood. In clinical trials, Belviq was found to be effective for weight loss, with participants losing an average of 5.8% of their body weight after a year. However, it is important to note that Belviq was discontinued in 2020 due to an increased risk of cancer detected in its users.
Obesity specialists consider Qsymia's 7.5-milligram dose of phentermine a reasonable risk for those without cardiovascular issues. In clinical trials, people taking Qsymia lost more weight than those taking Belviq. According to some experts, Qsymia users lost an estimated 10% of their body weight. However, the FDA notes that individuals who do not lose at least 3% of their body weight after three months of taking Qsymia are unlikely to achieve significant weight loss and should discontinue the drug or try a higher dose.
In summary, Belviq and Qsymia are both FDA-approved weight-loss drugs with different mechanisms of action. Belviq targets serotonin receptors in the brain to reduce appetite and increase feelings of fullness, while Qsymia contains phentermine and is designed to be used in conjunction with diet and exercise. While Belviq may be considered less risky in terms of side effects, Qsymia has shown greater weight-loss results in clinical trials. It is important to consult with a healthcare professional before taking any weight-loss medication to ensure it is safe and appropriate for your individual needs.
Diet Pills: How Many Americans Are Taking Them?
You may want to see also
Frequently asked questions
Belviq (lorcaserin) is a diet pill created by Arena Pharmaceuticals. It was approved by the FDA in June 2012. It causes weight loss by increasing levels of serotonin in the brain.
Qsymia is a diet pill made by Vivus Inc. It was approved by the FDA in July 2012. It combines two previously approved drugs: phentermine, an appetite suppressant, and topiramate, a seizure/migraine drug.
In clinical trials, people taking Qsymia lost more weight than those taking Belviq. On average, those taking Belviq lost 5.8% of their body weight after a year, while those taking Qsymia lost about 10%. However, Belviq may be considered less risky in terms of side effects. Ultimately, neither drug is for everyone, and it is recommended to consult a doctor about which pill to take.
